跳至主要内容
临床试验/NCT00323479
NCT00323479已完成4 期

A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX® (1mg/Day) as Adjuvant Treatment in Post Menopausal Women With Early Breast Cancer

AstraZeneca5 个研究点 分布在 1 个国家目标入组 114 人开始时间: 2006年6月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
AstraZeneca
入组人数
114
试验地点
5
主要终点
Number of Participants With New Events of Arthralgia

研究概览

简要总结

The purpose of this study is to describe the joint symptoms and structural joint changes under anastrozole as adjuvant treatment in postmenopausal women with early breast cancer.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole
  • WHO performance status 0, 1 or 2
  • Provision of written informed consent

排除标准

  • Recurrence of breast cancer, inflammatory rheumatism
  • treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, Herceptin
  • Diabetes treated by insulin
  • Severe renal or hepatic disease
  • Known hypersensitivity to anastrozole

结局指标

主要结局

Number of Participants With New Events of Arthralgia

时间窗: 12 months

次要结局

  • Functional Index of Cochin at 12 Months in Patients Under Anastrozole.(12 months)
  • Serum Collagen Degradation Type I - CTX-I at 12 Months in Patients Under Anastrozole(12 months)
  • Kellgren and Lawrence Score at 12 Months in Patients Under Anastrozole(12 months)
  • Synovial Membrane Thickness at 12 Months in Patients Under Anastrozole(12 months)
  • Percentage of Participant With Therapeutic Maintenance Under Anastrozole(12 months)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验